- Investing.com
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company’s product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Metrics to compare | PHGE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHGEPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.2x | −2.1x | −0.7x | |
PEG Ratio | −0.03 | −0.04 | 0.00 | |
Price/Book | 0.6x | 1.5x | 2.6x | |
Price / LTM Sales | - | 75.3x | 3.2x | |
Upside (Analyst Target) | - | 444.5% | 47.1% | |
Fair Value Upside | Unlock | 1.3% | 7.3% | Unlock |